Original Article: https://doi.org/10.1126/science.abc8059
- Sarcopenia is a condition characterized by age-related loss of skeletal muscle mass and function.
- Currently, sarcopenia treatments are lacking.
- Increase in enzyme that degrades prostaglandin is a hallmark of old tissues including skeletal muscle.
- The reduction of prostaglandin signaling is the main contributor to the reduction of muscle mass in aged mice.
- Researchers found that myofibers and interstitial cells within the old muscle produce the prostaglandin-degrading enzymes.
- Inhibition of prostaglandin-degrading enzymes increases aged muscle mass, strength, and performance.
- Inhibition of prostaglandin-degrading enzymes rejuvenated prostaglandin levels which increase mitochondrial function and damaged cell clean ups.
- Inhibition of prostaglandin-degrading enzymes also decreases ubiquitin-proteasome pathways which is associate with protein degradation.
- The study demonstrate how prostaglandin can counter muscle mass reduction.
- The result suggests that prostaglandin-degrading enzymes is a potential therapeutic target to treat sarcopenia.
Source:
Palla, A. R., Ravichandran, M., Wang, Y. X., Alexandrova, L., Yang, A. V., Kraft, P., Holbrook, C. A., Schürch, C. M., Ho, A., & Blau, H. M. (2020). Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength. Science (New York, N.Y.), eabc8059. Advance online publication. https://doi.org/10.1126/science.abc8059
https://pubmed.ncbi.nlm.nih.gov/25568649/
https://www.frontiersin.org/articles/10.3389/fnmol.2016.00004/full
